Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise

Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of treatment. The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2. Spinocerebellar Ataxia (SCA) is a rare neurodegenerative disease. It affects approximately 15,000 people in the U.S. and 24,000 in Europe and the U.K. Also Read: Biohaven Stock Stumb ...